Publications

Table of contents

1. Psychotic disorders
   1. Strategies for the Choice of Animal Models in the Evaluation ofAtypical Antipsychotic Drugs .S. Ahlenius
   2. Role of Olfactory Tubercle and Nucleus Accumbens in the effects ofClassical and Atypical Neuroleptics: search for regional specificity.A.R. Cools, E.P.M. Prinssen, B A. Ellenbroek and D J. Heeren
   3. Yawning induced by Low Doses of Apomorphine as a Possible BiologicalMarker for Studying the effects of CNS Active Compounds on theDopamine System .M. Casas, G. Prat, J. Guardia and P. Duro
   4. Remoxipride - Preclinical Predictions and Clinical Outcome .T.Lewander, D.M. Jackson, M. Blomqvist, S. Ogenstad and B. Gustafsson
   5. Potential Mechanisms underlying the Atypical Antipsychotic Profile ofRemoxipride .S.O. Ögren
   6. A Clinician's View of Animal Research in Schizophrenia Studies .T.Palomo
   7. Ondansetron: a double-blind, placebo-controlled study in acuteschizophrenia. .J. Wilson, P.G. Cooksey and S.L. McBain
   8. Clinical Characteristics of Atypical Antipsychotic Drugs .B.Woggon
   9. Sertindole -an Atypical Neuroleptic .C. Sánchez
2. Movement disorders
   10. Neuroanatomical Consequences of Psychostimulant Drugs: effects afteradult and prenatal exposure .P.M. Groves, D. Jackson, J.C. Linder,M.S. Manley, L.J. Ryan and S.J. Young
   11. The Peculiar Pharmacology of Bromocriptine .D.M. Jackson, J.A.Watson and S.B. Ross
   12. MPTP-induced Behavioural Deficits in Mice: validity and utility of amodel of parkinsonism .A. Fredriksson and T. Archer
   13. Huntington's Disease: behavioral pathology and animal models .D.F.Emerich, T.B. Freeman, D.W. Cahill, C.W. Olanow and P.R. Sanberg
   14. Parkinson's Disease: PET, pharmacokinetics and therapeutic strategies.S.M. Aquilonius
   15. Neurotrophic Factors for the Treatment of Neurological Disorders: themodel of Parkinson's disease .M. Angeles Mena, M. JoséCasajeros and J. Garcia de Yébenes
   16. Rehabilitation of Patients with Parkinson's .A. Portera-Sánchez
3. Cognitive disorders
   17. Critical Issues in Cognition Enhancing Drug Research .R.Porsolt,S. Roux and A. Lenègre
   18. Dopaminergic-Cholinergic Function in Neo-Striatal Memory Function:role of nigro-striatal terminals .N.M. White, M. Viaud and M.G.Packard
   19. Glutamatergic Receptors, Learning and Dementia: implications for theupdate of screening methods .W. Danysz and W.J. Schmidt
   20. Memory Processing by the Amygdala, Hippocampus and Entorhinal Cortex:role of glutamatergic and GABA-A receptors .I. Izquierdo
   21. Strategies "in Search of the Engram": a half-century later.R.W. Russell
   22. ACTH Neuropeptides and Recovery from Brain Injury .D. de Wied
   23. Effects of ACTH Neuropeptides on Nerve Repair and Neuropathy: animaland human studies .W.H. Gispen, A.C. Kappelle, B. Bravenboer,F.P.T. Hamers and P.M. Edwards
   24. Developing and Regenerating Systems as Models tor Trophic Effects ofACTH Neuropeptides .F.L. Strand, S.E. Alves, F.J. Antonawich, S.J.Lee, T.S. Lee and L.A. Zuccarelli
   25. The ICD-10 Classification of Dementias .J.J. López-Ibor
   26. Clinical Features of Alzheimer's Disease .D.G. Cole and J.H.Growdon